Politics

Tracking how politics and policy intersect with science and health care

Senate Drug Prices - Feb 26
Politics

In muted hearing, pharma execs dodge attempts to pin blame for high prices

By Lev Facher

Sen. Chuck Grassley
Politics

What questions will senators ask pharma executives? They gave us a preview

By Nicholas Florko

Primary care appointment
Politics

Medicare’s solution for saving primary care: blow up the office visit

By Casey Ross

1994 Tobacco Congress
Politics

‘A dark and elaborate art’: How pharma executives are training to avoid disaster at Tuesday’s congressional grilling

By Lev Facher and Nicholas Florko

Charles Grassley
Politics

Powerful Senate committee launches bipartisan probe into insulin pricing

By Nicholas Florko

Pharma CEO photo illustration
Politics

The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

By Damian Garde and Nicholas Florko

Pill Dollars
Politics

Drug spending could rise 6.1 percent annually by 2020, federal projections show

By Ike Swetlitz

Politics

Supreme Court deals a fatal blow to Maryland drug ‘price gouging’ law

By Lev Facher

Plasma IV
Politics

FDA: Young-blood transfusions provide ‘no proven clinical benefit’ for aging, Alzheimer’s

By Rebecca Robbins

Insulin NOVO NORDISK
Politics

‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around

By Nicholas Florko

human T cells in culture
Politics

Medicare would provide national coverage for CAR-T cancer therapies under new proposal

By Ike Swetlitz

U.S. Rep. Rosa DeLauro
Politics

NAFTA 2.0’s impact on drug prices is more complicated than some Democrats are implying

By Ike Swetlitz

FDA campus
Politics

Draft federal spending deal includes largest boost for FDA in five years

By Ike Swetlitz and Nicholas Florko

Pharmacy shelves
Politics

Defending the middlemen: JC Scott on testifying before Congress, challenging Trump, and revamping PBMs’ image

By Nicholas Florko

Booker and Sanders
Politics

The ‘Big Pharma’ candidate? As he runs for president, Cory Booker looks to shake his reputation for drug industry coziness

By Lev Facher

Optum
Pharmalot

A big PBM wants drug makers to agree to rebate demands that would preserve its bottom line

By Ed Silverman and Ike Swetlitz

Rep. Francis Rooney
Politics

An ambassador to the Vatican. A GOP megadonor. And now, a rare Republican joining Democrats to take on pharma

By Lev Facher

Sean Parker
Heavyweights

Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials

By Rick Berke

Alexandria Ocasio-Cortez
Biotech

A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Grace Eline
In the Lab

Trump’s $500 million for childhood cancer? Scientists have ideas how to spend it

By Sharon Begley

Sherrod Brown
Politics

Another potential 2020 hopeful, Sen. Sherrod Brown, backs a Medicare drug negotiation bill

By Lev Facher

National Institutes of Health Director Dr. Francis Collins
Politics

NIH asks inspector general to investigate 12 allegations of foreign influence in U.S. research

By Lev Facher

President Trump - New US-Mexico-Canada Trade Deal
Politics

Trump claims drug prices have fallen. But he’s cherry-picking that data

By Ike Swetlitz

Lloyd Doggett
Politics

As Trump calls on Congress to lower drug prices, some Democrats cheer. Others scoff

By Nicholas Florko and Lev Facher

Donald Trump State of the Union
Politics

Trump, claiming progress in lowering drug prices, tells Congress ‘we must do more’

By Ike Swetlitz

"Right To Try" Act - Matt Bellina
Politics

Prominent ‘right-to-try’ advocate is getting treatment under the new law

By Nicholas Florko

Iowa Baby Brothers
Don't Miss

With time ticking away, clinicians scramble to save newborn twins from the disease that took their brother

By Rebecca Robbins

Charles Grassley
Politics

Congress wants these 7 drug company CEOs to testify about prices

By Lev Facher

Bernie Sanders
Pharmalot

Sanders accuses a drug maker of ‘immoral exploitation’ for the price of a rare disease drug

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy